Overview
Lobbying Costs
1,375,000€
Financial year: Jan 2017 - Dec 2017
Lobbyists (Full time equivalent)
4.25 Fte (10)
Lobbyists with EP accreditation
3
High-level Commission meetings
3
Lobbying Costs over the years
-
Info
Amgen Inc
EU Transparency Register
42243575237-50 First registered on 07 Feb 2011
Goals / Remit
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.Main EU files targeted
Engage governments and policy makers worldwide on issues important to Amgen to:
Ensure patients have access to medicines they need
Provide coverage and reimbursement that reward innovation
Introduce sound, science-based regulation
Enable biotechnology research and development (R&D)Address
Head Office
One Amgen Center Drive
Thousand Oaks, California 91320-1799
UNITED STATESEU Office
Telecomlaan 5-7
Diegem 1831
BELGIUM -
People
Total lobbyists declared
10
Employment time Lobbyists 75% 2 50% 3 25% 5 Lobbyists (Full time equivalent)
4.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
3 accreditations were / are live (in bold) for the selected state of 08 May 2018
Name Start date End Date Nicholas COSENZA 23 Sep 2023 20 Sep 2024 Viktoria TZOUMA 09 Mar 2024 07 Mar 2025 Vincent MARTICHOU 13 Jul 2023 12 Jul 2024 Viktoria TZOUMA 02 Feb 2023 02 Feb 2024 Marie Helene FANDEL 26 Feb 2019 01 Feb 2020 Douglas GREGORY 24 Jan 2019 24 Jan 2020 Mr Jamie Nathan WILKINSON 20 Nov 2018 20 Nov 2019 Vincent MARTICHOU 27 Mar 2018 30 Mar 2019 Marie Helene FANDEL 16 Feb 2018 16 Feb 2019 Douglas GREGORY 30 Jan 2018 24 Jan 2019 Douglas GREGORY 25 Feb 2017 30 Jan 2018 Marie Helene FANDEL 25 Feb 2017 16 Feb 2018 Janusz LINKOWSKI 05 Sep 2016 26 Aug 2017 Douglas GREGORY 14 Jan 2016 13 Jan 2017 Marie Helene FANDEL 16 Sep 2015 14 Sep 2016 Janusz LINKOWSKI 05 Sep 2015 03 Sep 2016 Ms JOANA MARIA GANDARA LEITAO PAIVA 23 Jan 2015 23 Oct 2015 Douglas GREGORY 23 Jan 2015 14 Jan 2016 Ms JOANA MARIA GANDARA LEITAO PAIVA 15 Mar 2014 23 Jan 2015 Douglas GREGORY 01 Mar 2014 23 Jan 2015 Douglas GREGORY 07 Mar 2013 28 Feb 2014 Complementary Information
Following the Transparency Register implementing guidelines, released on 5 October 2015, Amgen has reviewed its financial data regarding activities under the scope of Article 7 of the Inter-Institutional Agreement published in the official journal of 19 September 2014.
The estimated annual costs arising from activities covered by the Register cover direct and indirect lobbying.
Amgen calculated our total costs (as per the TR guidelines) by adding up the following elements:
1. Staff costs (73% of EU Public Affairs expenditures): based on the full-time equivalents (FTEs) already declared.
2. Office and administrative expenses (5% of EU Public Affairs Expenditures): rent and utilities, supplies and materials.
3. In-house operational expenditure (1% of EU Public Affairs expenditures): cost of advocacy, PR or public affairs campaigns, marketing and advertising, use of media, organisation of events, publications, etc.
4. Representation costs (0% of EU Public Affairs expenditures): expenses incurred through taking part in events and meetings.
5. Outsourced activity costs (8% of EU Public Affairs expenditures): fees for consultants and subcontractors.
6. Membership and related fees (13% of EU Public Affairs expenditures): fees for joining relevant networks and structures.
7. Other relevant costs (0% of EU Public Affairs expenditures)
This new estimate follows and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Because there is no de minimus rule, we have tried to identify and report the number of Amgen employees who are covered by the scope of the Transparency Register in the execution of their work responsibilities.Person in charge of EU relations
Mr Douglas Gregory (Executive Director European Union Government Affairs)
Person with legal responsibility
Mr Robert Bradway (Chairman and Chief Executive Officer)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Amgen is a member of the following organizations in Brussels:
American Chamber of Commerce to the EU
EBE – European Biopharmaceutical Enterprises
EFPIA – European Federation of Pharmaceutical Industries and Associations
Eucope - European Confederation of Pharmaceutical Entrepreneurs
EuropaBio
Science Business - brings together industry research and policy
The Kangaroo Group
Transatlantic Policy NetworkMember organisations
None declared
-
Financial Data
Closed financial year
Jan 2017 - Dec 2017
Lobbying costs for closed financial year
1,375,000€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
None
Other activities
None declared
- Meetings
Meetings
3 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 08 Jul 2022 Location call Subject pharmaceutical supply chains Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Maurits-Jan Prinz (Cabinet member)
-
Date 12 Jun 2020 Location Videoconference Subject Videoconference CEO of Amgen and CEO of Teneo (Topic: Preparation of Global Pledging Summit on 27 June) Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Ursula von der Leyen (President)
Other Lobbyists -
Date 17 May 2018 Location Brussels Subject Digital Health Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Digital Economy and Society Attending - Manuel Mateo-Goyet (Cabinet member)
- Meetings